Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
3
×
clinical trials
fda
3
×
life sciences
national blog main
amgen
boston top stories
drugs
eli lilly
indiana blog main
indiana top stories
lasmiditan
migraine research foundation
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
teva pharmaceutical
triptans
akcea therapeutics
alder biopharmaceutical
allergan
alnylam pharmaceuticals
alprazolam
american academy of neurology
atogepant
barry greene
biohaven
bob azelby
boston
boston university
botox
boulder/denver blog main
boulder/denver top stories
What
decades
3
×
fda
approval
drug
friday
migraine
new
won
acute
addresses
ago
alnylam
approve
arguments
awaits
big
biological
causes
class
commercialized
companies
competitors
condition
crossed
decision
discovered
drugs
eli
fingers
giant
giving
historic
lasmiditan
lilly
lilly’s
make
medication
medicine
meeting
neuro
Language
unset
Current search:
decades
×
fda
×
" boston blog main "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision